| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
DAGLβ-IN-1 targets diacylglycerol lipase-β (DAGLβ), a serine hydrolase that catalyzes the hydrolysis of diacylglycerol (DAG) to produce 2-arachidonoylglycerol (2-AG). 2-AG is a key endocannabinoid that activates cannabinoid receptors CB1 and CB2. By inhibiting DAGLβ, the compound reduces 2-AG production, thereby modulating endocannabinoid signaling. This makes DAGLβ-IN-1 a valuable tool for studying the role of 2-AG in various physiological and pathological processes.
|
|---|---|
| ln Vitro |
The primary enzyme responsible for the biosynthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG) is called Diacylglycerol lipase-β (DAGLβ) [1].
DAGLβ-IN-1 exhibits in vitro activity as a DAGLβ inhibitor. Its activity is assessed in enzyme assays measuring DAGLβ-mediated hydrolysis of DAG to 2-AG. The compound's potency is determined by measuring the decrease in 2-AG production in the presence of varying concentrations of the inhibitor. It serves as a versatile intermediate for the design of DAGL-tailored activity-based probes, which are used to study DAGL activity in complex biological samples. |
| ln Vivo |
In vivo activity of DAGLβ-IN-1 is primarily studied in the context of its use as a tool for designing activity-based probes, rather than as a therapeutic agent. These probes can be used to visualize and quantify DAGLβ activity in animal tissues. The compound's role in modulating endocannabinoid signaling may have implications for studying pain, inflammation, and neurological disorders.
|
| Enzyme Assay |
In vitro enzyme assays for DAGLβ-IN-1 involve measuring its inhibition of DAGLβ activity. These assays use recombinant DAGLβ or tissue lysates and a fluorogenic or radiolabeled DAG substrate. The enzyme is incubated with the substrate and varying concentrations of DAGLβ-IN-1. The production of 2-AG or the decrease in substrate is measured to determine the IC50. Activity-based probe labeling studies can also be performed using DAGLβ-IN-1-derived probes.
|
| Cell Assay |
In vitro cellular assays for DAGLβ-IN-1 are conducted in cells expressing DAGLβ, such as neurons or macrophages. Cells are treated with the compound, and 2-AG levels are measured by LC-MS. The compound's effects on endocannabinoid signaling can be assessed by measuring downstream signaling events, such as ERK phosphorylation or calcium mobilization. Activity-based probes derived from DAGLβ-IN-1 can be used to label DAGLβ in cell lysates.
|
| Animal Protocol |
In vivo animal experiments with DAGLβ-IN-1 are limited, as the compound is primarily used as an intermediate for probe design. However, activity-based probes derived from DAGLβ-IN-1 can be administered to animals to study DAGLβ activity in tissues. These studies can provide insights into the role of DAGLβ in various physiological and pathological processes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for DAGLβ-IN-1 are limited, as the compound is primarily used as a research intermediate. It has a molecular weight of 561.60 and a molecular formula of C28H34F3N5O4. The compound is soluble in DMSO and is typically stored at -20°C. Its half-life and bioavailability have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for DAGLβ-IN-1 are limited. The compound is intended for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound. Further toxicity studies would be required to support any potential clinical development.
|
| References |
|
| Additional Infomation |
DAGLβ-IN-1 is an inhibitor of diacylglycerol lipase-β (DAGLβ), the principal biosynthetic enzyme for the endocannabinoid 2-AG. It serves as a versatile intermediate for the design of DAGL-tailored activity-based probes. The compound has a molecular weight of 561.60 and is available in high purity (>98%). It is used in research to study the endocannabinoid system and to develop tools for visualizing DAGL activity.
|
| Molecular Formula |
C28H34F3N5O4
|
|---|---|
| Molecular Weight |
561.595877170563
|
| Exact Mass |
561.256
|
| CAS # |
1402612-61-6
|
| PubChem CID |
56643167
|
| Appearance |
Off-white to light yellow ointment
|
| LogP |
6.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
40
|
| Complexity |
781
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NUWWTGPNHRKNPN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C28H34F3N5O4/c1-27(2,3)40-25(37)32-17-8-5-9-18-35(19-16-21-10-6-4-7-11-21)26(38)36-20-24(33-34-36)22-12-14-23(15-13-22)39-28(29,30)31/h4,6-7,10-15,20H,5,8-9,16-19H2,1-3H3,(H,32,37)
|
| Chemical Name |
tert-butyl N-[5-[2-phenylethyl-[4-[4-(trifluoromethoxy)phenyl]triazole-1-carbonyl]amino]pentyl]carbamate
|
| Synonyms |
DAGLβIN1; DAGLβ IN 1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7806 mL | 8.9031 mL | 17.8063 mL | |
| 5 mM | 0.3561 mL | 1.7806 mL | 3.5613 mL | |
| 10 mM | 0.1781 mL | 0.8903 mL | 1.7806 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
